Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 28, 2019	Dec. 28, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration, Liability, Current	$ 52.4
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent Consideration, Liability, Noncurrent	78.0
Level 3 | Recurring | Contingent Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	151.4
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	(25.0)
Accretion expense	1.7
Fair value adjustment	2.3
Ending balance	130.4
Questcor Pharmaceuticals, Inc. | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent liability	52.9	$ 76.2
StrataGraft [Member] | Stratatech | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent liability	55.6	53.7
MNK-6105 [Member] | Ocera [Member] | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent Consideration, Liability	21.9	$ 21.5
Maximum | Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Milestone Payment	$ 90.0